

Except for US patent documents, a copy of each listed reference is enclosed or submitted herewith.

Copyrighted material submitted with this Information Disclosure Statement may be delivered to the Government under license from the Copyright Clearance Center, Inc., or other rights holders – no further reproduction of such works is permitted.

Inclusion of any reference is not intended to constitute an admission that the reference is "prior art" unless it is specifically designated as such.

This information disclosure statement is being filed **after** the period set forth in 37 C.F.R. 1.97(b), but **before** the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution.

Accompanying this information disclosure statement is the fee set forth in 37 C.F.R. § 1.17(p) (currently \$180.00), as per the requirements of 37 C.F.R. 1.97(c). The Examiner is hereby authorized to charge Deposit Account No. 14-1447 in the amount of \$180.00. No further fees are due. However, please charge any fees should they be required, to Novo Nordisk Inc. Deposit Account No. 14-1447.

Applicant(s) respectfully request(s) that any references or other information listed above be made of record in this patent application. The Examiner is invited to call the undersigned if there are any questions concerning this submission or application.

Respectfully submitted,

Date: November 5, 2009

/Shelby J. Walker, Reg. No. 45,192/

Shelby J. Walker, Reg. No. 45,192

Novo Nordisk Inc.

Customer Number 23650

(609) 987-4883